Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Purpose: The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed testicular germ cell tumors (GCTs). Patients and Methods: Forty-six patients with progressive metastatic GCTs were treated with paclitaxel and ifosfamide plus cisplatin (TIP) as second-line therapy. Eligibility required that patients have both a testis primary tumor site and a prior complete response (CR) to a first-line chemotherapy program, which had been identified previously as favorable prognostic factors to conventional-dose salvage chemotherapy. Results: Thirty-two (70%) of 46 patients achieved a CR to treatment. Three patients (7%) who achieved a CR relapsed after TIP chemotherapy. Twenty-nine patients are continuously disease free at a median follow-up time of 69 months, resulting in a 63% durable CR rate and a 2-year progression-free survival rate of 65% (95% CI, 51% to 79%). Conclusion: Four cycles of TIP as second-line therapy achieved a durable CR rate in a high proportion of patients with relapsed testicular GCT. The high CR rate emphasizes the importance of patient selection according to prognostic factors to achieve a favorable outcome to conventional-dose salvage therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Self-citationChou, T.-C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1517 · Cited by 524
Self-citationVinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Late relapse of testicular cancer.
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1170 · Cited by 331
Beyer, J., Schwella, N., Zingsem, J., Strohscheer, I., Schwaner, I., Oettle, H., Serke, S., Huhn, D., & Stieger, W. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1328 · Cited by 269
Motzer, R. J., Sheinfeld, J., Mazumdar, M., Bains, M., Mariani, T., Bacik, J., Bajorin, D., & Bosl, G. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2413 · Cited by 253
Self-citationChemotherapy for Teratoma With Malignant Transformation
Donadio, A. C., Motzer, R. J., Bajorin, D. F., Kantoff, P. W., Sheinfeld, J., Houldsworth, J., Chaganti, R. S. K., & Bosl, G. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.019 · Cited by 236
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Peccatori, F. A., Azim, H. A., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt199 · Cited by 790
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Horwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds579 · Cited by 320
Guidelines on Testicular Cancer
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.019 · Cited by 314
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., De Giorgi, U., Fléchon, A., Margolin, K., Lotz, J.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6678 · Cited by 273
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
Systemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
“Testicular germ cell tumours (GCTs) have an exceptional sensitivity to platinum-based chemotherapy (Einhorn, 1979, 1990; Kondagunta et al, 2005; Mardiak et al, 2005; Mead et al, 2005).”
BackgroundPhase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81
Siska, P. J., Johnpulle, R. A. N., Zhou, A., Bordeaux, J., Kim, J. Y., Dabbas, B., Dakappagari, N., Rathmell, J. C., Rathmell, W. K., Morgans, A. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1305535 · Cited by 82
Chi, E. A., & Schweizer, M. T. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.04.005 · Cited by 37
Cursano, M. C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gallà, V., Santini, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01325 · Cited by 19
“CDCT can induce long-term remissions in 30–50% (3, 4) as second-line therapy, but its efficacy is inferior in patients with multiple relapsed or cisplatinrefractory GCT (5, 6).”
Background
Metadata
- Authors
- Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-20
- Volume
- 23
- Issue
- 27
- Pages
- 6549-6555
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2168588194
- Cited by
- 418
- References
- 18
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.